EMAIL THIS PAGE TO A FRIEND

Tissue engineering. Part A

Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells.


PMID 25517798

Abstract

The limited regenerative capacity of articular cartilage contributes to progressive joint dysfunction associated with cartilage injury or osteoarthritis. Cartilage tissue engineering seeks to provide a biological substitute for repairing damaged or diseased cartilage, but requires a cell source with the capacity for extensive expansion without loss of chondrogenic potential. In this study, we hypothesized that decreased expression of the cell cycle inhibitor p21 would enhance the proliferative and chondrogenic potential of differentiated induced pluripotent stem cells (iPSCs). Murine iPSCs were directed to differentiate toward the chondrogenic lineage with an established protocol and then engineered to express a short hairpin RNA (shRNA) to reduce the expression of p21. Cells expressing the p21 shRNA demonstrated higher proliferative potential during monolayer expansion and increased synthesis of glycosaminoglycans (GAGs) in pellet cultures. Furthermore, these cells could be expanded ∼150-fold over three additional passages without a reduction in the subsequent production of GAGs, while control cells showed reduced potential for GAG synthesis with three additional passages. In pellets from extensively passaged cells, knockdown of p21 attenuated the sharp decrease in cell number that occurred in control cells, and immunohistochemical analysis showed that p21 knockdown limited the production of type I and type X collagen while maintaining synthesis of cartilage-specific type II collagen. These findings suggest that manipulating the cell cycle can augment the monolayer expansion and preserve the chondrogenic capacity of differentiated iPSCs, providing a strategy for enhancing iPSC-based cartilage tissue engineering.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

97622
2-Mercaptoethanol, for HPLC derivatization, ≥99.0% (GC)
C2H6OS
BP578
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
C22H29FO5
D0700000
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
C22H29FO5
1176007
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
C22H29FO5
46165
Dexamethasone, VETRANAL, analytical standard
C22H29FO5
31375
Dexamethasone, tested according to Ph.Eur.
C22H29FO5
PHR1526
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
C22H29FO5
Y0001593
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
C22H29FO5
Y0001177
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
C22H29FO5
P0380
L-Proline, ReagentPlus®, ≥99% (HPLC)
C5H9NO2
P5607
L-Proline, from non-animal source, meets EP, USP testing specifications, suitable for cell culture
C5H9NO2
P8865
L-Proline, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C5H9NO2
1568506
L-Proline, United States Pharmacopeia (USP) Reference Standard
C5H9NO2
81709
L-Proline, BioUltra, ≥99.5% (NT)
C5H9NO2
93693
L-Proline, certified reference material, TraceCERT®
C5H9NO2
W331902
L-Proline, 99%, FCC, FG
C5H9NO2
PHR1332
L-Proline, Pharmaceutical Secondary Standard; Certified Reference Material
C5H9NO2
C7974
Monoclonal Anti-Collagen, Type X antibody produced in mouse, clone COL-10, ascites fluid